Publicacions en col·laboració amb investigadors/ores de Karolinska University Hospital (17)

2025

  1. Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

    The New England journal of medicine, Vol. 392, Núm. 18, pp. 1777-1788

2023

  1. Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study

    Leukemia and Lymphoma

  2. Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 19, Núm. 12, pp. 811-818

2022

  1. Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

    Haematologica, Vol. 107, Núm. 10, pp. 2408-2417

  2. Teclistamab in Relapsed or Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505

2021

  1. Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients

    Journal of Clinical Pharmacology, Vol. 61, Núm. 5, pp. 614-627

  2. Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results

    Journal of Cancer Research and Clinical Oncology, Vol. 147, Núm. 2, pp. 619-631

  3. Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study

    Annals of Hematology, Vol. 100, Núm. 4, pp. 1065-1077

  4. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)

    Haematologica, Vol. 106, Núm. 6, pp. 1725-1732

  5. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

    The Lancet, Vol. 398, Núm. 10301, pp. 665-674

  6. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118

2020

  1. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

    The Lancet Haematology, Vol. 7, Núm. 5, pp. e370-e380

2019

  1. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

    Blood, Vol. 134, Núm. 8, pp. 668-677

2017

  1. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study

    Leukemia, Vol. 31, Núm. 11, pp. 2443-2448

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

  2. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

    Drugs, Vol. 76, Núm. 8, pp. 853-867

2014

  1. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

    The Lancet Oncology, Vol. 15, Núm. 12, pp. e538-e548